Current trends in the pathogenetic therapy of anxiety disorders. Part 2
Abstract
The aim was to present the current foreign and domestic literature data on the treatment of anxiety-depressive spectrum disorders in part 2 of the review.
Results. Various classes of drugs with anxiolytic and antidepressant effects were considered as well as their advantages and disadvantages. Special attention was paid to the peptide regulation of anxiety as one of the perspective directions concerning the development of new drugs with anxiolytic activity. In this vein, the data of our own study, regarding the efficacy and safety of therapy of patients with anxiety-hypochondriac disorders using peptide drug Selank in combination with benzodiazepine tranquilizer phenazepam, was presented.
Conclusions. The obtained data expands the possibilities of pathogenetic therapy of anxiety spectrum disorders.
About the Authors
O. N. Tereshchenko
FSBSI “Mental Health Research Centre”
Russian Federation
Russian Federation
Tereshchenko Olessya N. - MD, laboratory of Pathophysiology.
Moscow.
N. V. Kost
FSBSI “Mental Health Research Centre”
Russian Federation
Russian Federation
Kost Natalya V. - doctor of biological sciences, Professor.
Moscow.
V. E. Medvedev
FNMO Medical Institute, “Peoples’ Friendship University of Russia”
Russian Federation
Russian Federation
Medvedev Vladymyr E. - PhD, MD, Associate Professor, Department of Psychiatry, psychotherapy and psychosomatic pathology.
Moscow.
References
1. Noyes R., Clanc J., Hoenk P.R., Slymen D.J. The prognosis of anxiety neurosis. Archives of General Psychiatry. 1980;37(2):173-178.
2. Wittchen H.U., Carter R.M., Pfister H., Montgomery S.A., Kessler R.C. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin. Psychopharmacol. 2000;15(6):319-328.
3. Pogosova G.V. Modern approaches to diagnosis and treatment of depressive disorders in both practices. Manual for doctors. FGU GNITS profilakticheskoy meditsiny Roszdrava, 2015 (In Russ.)
4. Olsen R. W., Betz H. GABA and glycine. In: Siegel G.J., Albers R.W., Brady S., Price D.D. (eds.). Basic Neurochemistry: molecular, cellular and medical aspects. 7th. Elsevier; 2006:291-302.
5. Avedisova A.S., Yastrebov D.V., Kostacheva Ye.A. Pharmacoepidemiological analysis of outpatient appointments tranquilizers benzodiazepine group in psychiatric institutions. Ros. Psikhiatricheskiy zhurnal. 2005;4:10-12 (In Russ.)
6. Ashton H. Drug dependency: benzodiazepines. In: Ayers S., Baum A., McManus C., Newman S. (eds.). Cambridge Handbook of Psychology, Health and Medicine. 2nd. ed. Cambridge University Press, 2007:675-678.
7. Gilman A.G. (ed.) Clinical Pharmacology. Vol. 1. M.: Praktika, 2006 (In Russ.)
8. Andronati S.A. (ed.) Gidazepam. Kiev: Naukova dumka, 1992 (In Russ.)
9. Smulevich A.B., Drobizhev M.Yu., Ivanov S.V. (eds.) Clinical effects of benzodiazepine tranquilizers in psychiatry and general medicine. M.: Media Sfera, 2005 (In Russ.)
10. Ramakrishnan K., Shield D.C. Treatment options for insomnia. American Family Physician; 76(4):517-526.
11. Argyropoulos S.V., Sandford J.J., Nutt D.J. The psychobiology of anxiolytic drugs. Part 2: pharmacological treatments of anxiety. PharmacoL Ther. 2000;88:213-227.
12. Rational pharmacotherapy in psychiatric practice: a guide for clinicians, (eds.) Aleksandrovskiy Yu.A., Neznanov N.G. M.: Litterra, 2014 (In Russ.)
13. Piskunov M.V., Krivenkov A.N., Reykhel' N.V. Dependence on pregabalin («lyrics»): a review of the literature and own clinical observations. Narkologiya. 2013;4:52-56 (In Russ.)
14. Seredenin S.B., Voronin M.V. Neuroreceptor mechanisms of the afobazole effect Ekspenmental'naia i klinicheskaia farmakologiia. 2009;72(1):3—11 (In Russ.)
15. Kovalev G.I., Starikova N.A. Pantogam-aktiv mechanism of pharmacological actions. RMZH: nevrologiya. 2010;18(21):l-4 (In Russ.)
16. Voronina T.A. Antioxidant mexidol Basic neuropsychotropic effects and mechanism of action. Psikhofarmakologiya. Biol. narkologiya. 2001;1(1):2-12 (In Russ.)
17. Rickels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam. Archives of General Psychiatry. 1993;50(ll):884-895.
18. Mosolov S.N. (ed.) Guide to psychopharmacological and antiepi-leptic drugs authorized for use in Russia. 2nd ed. M.: Izdatelstvo «Binom», 2004 (In Russ.)
19. Leiblum S.R. Principles and practice of sex therapy. 4th ed. New York: The Guilford Press, 2006.
20. Avedisova A.S., Zakharova K.V., Marachev M.P. Efficacy of valdoxan (agomelatine) when treating patients with anxiety depression within major depressive disorder: results from the program «Jazz». Psikhiatriya ipsikhofarm. 2009;6:15-19 (In Russ.).
21. European public report — valdoxan. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6. pdf
22. Millan M.J. Anxiolitic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blocade. Psychopharmacology. 2005; 177:448- 459.
23. Psychiatry: A two-volume manual for physicians. Tiganov A.S. (ed.) Moscow: ОАО Meditsina Publisher, 2012 (In Russ.)
24. Gershon S., Eison A.S. Anxiolytic profiles. J. Clin. Psychiatry. 1983;44(11, Pt 2):45-57.
25. Reinscheid R.K. Pharmacological characterization of human and murine neuropeptides receptor variants. J. Pharmacol. Exp. Ther. 2005;315(3):1338-1345.
26. Ashmarin I.P. Biochemistry of the brain: TutoriaL Ashmarin I.P., Stukalov P.V., Yeshchenko N.D. (eds.) SPb.: Izd-vo SPb. un-ta, 1999 (In Russ.)
27. Kost N.V., Meshavkin V.K., Zozulya A.A. Neuropeptides in regulating anxiety. Psikhiatriya. 2010;4:64-75 (In Russ.)
28. Aboufatima R., Chait A., Dalai A., De Beaurepaire R. Calcitonininduced impairment in conditioning is antagonized by chronic antidepressant drug treatment Therapie. 1999;54(5):573-577.
29. Gomazkov O.A. Functional biochemistry of regulatory peptides. M.: Nauka, 1993 (In Russ.)
30. Strohle A., Feller C., Strasburger C.J., Heinz A., Dimeo F. Anxiety modulation by the heart? Aerobic exercise and atrial natriuretic peptide. Psycho neuroendocrinology. 2006;31 (9): 1127-1130.
31. Wiedemann К., Jahn Н« Kellner М. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behavior. Exp. Clin. Endocrinol. Diabetes. 2000;108(1):5-13.
32. Seredenin S.B. Creating new anxiolytics on the base of multifactor control of anxiety reactions. Psikhofarmakologiya i biologicheskaya narkologiya. 2007;7:1944 (In Russ.)
33. Kamenskiy A.A., Antonova L.V., Samoylova N.A., Galkin O.M., Andreyev S.M, Ashmarin I.P. Exitatory action of taftsin on the activity of white rats. Byulleten' eksperimental'noy biologii i meditsiny. 1980;89(7):43-45. (I n Russ.)
34. Turovetskiy V.B., Zolotilin S.A., Sarycheva N.Yu, Kamenskiy A.A. Influence of taftsin on the functional activity and intracellular pH of mice peritoneal macrophages. Byulleten' eksperimental'noy biologii i meditsiny. 1994;117(3):265-267 (In Russ.)
35. Cillari E., Arcoleo E., Dieli M. The macrophage activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasites in vitro. Infect. Immun. 1994;62(6): 2649-2652.
36. Nishioka K., Amoscato A.A., Babcock G.F., Banks R.A., Phillips J.H. Tuftsin: an immunomodulating peptide hormone and its clinical potential as a natural biological response modifier. Cancer Invest. 1984;2(1): 39-49.
37. Val'dman A.V., Kozlovskaya M.M., Ashmarin I.P., Mineyeva M.F., Anokhin K.V. Central effects tetrapeptide taftsin. Byulleten'eksperimental'noy biologii i meditsiny. 1981;92(7):31—33 (In Russ.)
38. Klusha V.Ye. Peptides — regulators of brain functions. Riga:Z-inyatiye, 1984 (In Russ.)
39. Semenova T.P. Optimization of the processes oflearning and memory. Pushchino: ONTI GSHTS RAN, 1992 (In Russ.)
40. Kozlovskaya M.M., Seredenin S.B., Kozlovskiy I.I., Val'dman E.A., Andreyeva L.A., Myasoyedov N.F. Comparative study of the taftsin fragments influence on conditional passive avoidance reactions. Khimiko-farmatsevticheskiy zhumal. 2001;35(3):3-5 (In Russ.)
41. Val’dman A.V., Aleksandrovskiy K.A. Drug therapy of neurotic disorders. M.: Meditsina, 1987 (In Russ.)
42. Kozlovskaya M.M., Kozlovskii I.I., Val'dman E.A. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci. Behav. Physiol. 2003;33(9):853-860.
43. Seredenin S.B., Kozlovskaya M.M., Semenova T.P. Particularly of anxiolytic action of taftsin and its analogue TP-7 on behavior and serotonin exchange in the brain of rats with chronic serotonergic activity system deprivation. Eksperimental'naya i klinicheskaya farmakologiya. 1995;58(6):3-6 (In Russ.)
44. Sokolov O. Yu., Meshavkin V.K., Kost N.V., Zozulya A.A. A comparative analysis of the behavioral effects of Selank and its action on the activity of enkephalindegrading enzymes in blood plasma of mice with different emotional stress reactions phenotype. Byul. eksperimental'noy biologii i meditsiny. 2002; 133(2): 158- 161 (In Russ.)
45. Seredenin S.B., Kozlovskaya M.M., Shcherbakova O.V. Comparative impact of heptapeptide TP-7 and its dosage form on learning, memory and behavior of rats with intact research and destroyed catheholaminergic system. Khim.-farm zhurn. 1996;30(5):12-14 (In Russ.)
46. Neznamov G.G., Teleshova Ye.S., Bochkarev V.K., Kozlovskaya M.M., Koshelev V.V. Results of clinical pharmacological studies of peptide drug selank as anxiolytic. Sots, i klin. Psikhiatriya. 2003;4:28-36 (In Russ.)
47. Zozulya A.A., Neznamov G.G., Syunyakov T.S., Kost N.V., Gabaeva M.V., Sokolov O.Yu., Serebryakova E.V., Siranchieva O.A., Andryuschenko A.V., Teleshova Ye.S., Syunyakov S.A., Smulevich A.B., Myasoedov N.F., Seredenin S.B. Efficacy and mechanisms of action of new peptide anxiolytic Selank in the treatment of gen¬eralized anxiety disorder and neurasthenia. Zhumal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;4:16-22 (In Russ.)
48. Teleshova E.S., Bochkarev V.K., Sjunjakov T.S., Bugaeva T.P., Neznamov G.G. Results of clinical pharmacological studies of peptide drug selank. Psychiatry. 2010;4:26-35 (In Russ.)
49. Medvedev V.E., Tereshchenko O.N., Israyelyan A.Yu., Chobanu I.K., Kost N.V., Sokolov O.YU., Myasoyedov N.F. Anxiolytic effect and tolerability of Selank compared with phenazepamin the treatment of anxiety disorders. Zhumal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(7):17-22 (In Russ.)
50. Medvedev V.E., Tereshchenko O.N., Israyelyan A.Yu., Chobanu I.K., Kost N.V., Sokolov O.Yu., Myasoyedov N.F. Optimization of anxiety disorders therapy by peptide drug Selank. Zhurnal nevrologii ipsikhiatrii im. S.S. Korsakova. 2015;115(6):33-40 (In Russ.) doi: 10.mi6/jnevro20151156133-40
51. Zolotarev Iu.A., Dadaian A.K., Dolotov O.V. и др. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Bioorg. Khim. 2006;32(2):183-191 (In Russ.)
52. Kolomin T.A., Agapova T.Iu., Agniullin Ia.V., Shram S.I., Shadrina M.I., SlominskiT P.A., Limborskaia S.A., Miasoedov N.F. Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank. Zh. Vyssh. Nerv. Deiat. im. I.P. Pavlova. 2013;63(3):365-374 (In Russ.)
53. Narkevich V.B., Kudrin V.S., Klodt P.M., Pokrovskiy A.A., Kozlovskaya M.M., Mayskiy A.I., Rayevskiy K.S. Influence of heptapeptide selank on monoamine and their metabolites content in the brain of mice BALB/C and C57BI/6. A comparative study. Eksperimental’naya i klinicheskaya farmakologiya. 2008; Л(5):8-12 (In Russ.)
54. Uchakina O.N., Uchakin P.N., Miasoedov N.F., Andreeva L.A., Shcherbenko V.E., Mezentseva M.V., Gabaeva M.V., Sokolov O.Iu., Zozulya A.A., Ershov F.I. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhumal nevrologii i psikhiatrii im. S.S. Korsakova. 2008; 108(5): Л-75 (In Russ.)
55. Otman I.N., Zozulya S.A., Sarmanova Z.V., Klushnik T.P. Inflammatory and autoimmune reactions in different forms of nervous system functioning disorders. Patol. Fiziol. Eksp. Ter. 2015;(3):81-88 (In Russ.)
56. Tiganov A.S., Kopeiko G.I., Brusov O.S., Klyushnik T.P. New findings in the study of the pathogenesis and treatment of endogenous depression. Zhumal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(11):65—72 (In Russ.)
Review
For citations:
Tereshchenko O.N., Kost N.V., Medvedev V.E. Current trends in the pathogenetic therapy of anxiety disorders. Part 2. Psychiatry (Moscow) (Psikhiatriya). 2018;(78):106-115. (In Russ.)
Views:
878
Email this article 
